VIRUS AND OTHER INFECTION-ASSOCIATED CANCERS RESEARCH PROGRAM PROGRAM CODE: VOIC PROJECT SUMMARY/ABSTRACT The Virus and Other Infection-associated Cancer (VOIC) Research Program explores associations between microbial infections and human cancer and accelerates clinical applications of basic science findings. The program brings together 27 outstanding investigators from four different schools focused on cancer-associated microbial pathogens, immunology, and translational and implementation science. The previously designated ?Molecular Virology? research program was most recently ranked Outstanding to Exceptional, with strong research in nearly all human tumor viruses. In recognition of the emerging and important role of bacteria in tumorigenesis, the program name was changed from ?Molecular Virology? to ?Virus and Other Infection- associated Cancers? (VOIC). In the current funding period, VOIC program accomplishments include improved understanding of underlying causal relationships between microbial infections and human cancer that has provided new mechanism-based insights for therapeutic and preventive cancer interventions, including vaccines. The link between microbial infections and cancer is well established for seven human tumor viruses that cause up to ~15% of all human cancer. Nine program members study human tumor viruses, contributing fundamental insights into latency, cell growth, and carcinogenesis. Current research also focuses on a better understanding of the role of human papillomaviruses (HPV) in oropharyngeal cancer, as well as immune responses to viral infections?research that will assist with the development of effective vaccines. Since emergence of the HIV/AIDS pandemic and its associated cancers, the VOIC program has aimed to understand basic mechanisms of HIV infection, pathogenesis, and immune modulation to develop strategies to decrease the significant cancer burden associated with HIV. VOIC has been at the forefront in defining a shift in cancers from classic AIDS-defining cancers to non?AIDS-defining cancers in aging patients on long-term antiretroviral therapy (ART). Nine program members work at the interface of HIV/AIDS and cancer, performing both basic and translational research towards a cure and a vaccine, as well as advancing clinical trials. Bacterial associations with human cancer have been frequently observed in gastric cancer, colorectal cancer, and gallbladder cancer, but causal relationships are less well understood. To foster research in this important area, five program members were recruited to VOIC to study the human microbiome and cancer and translate microbiome research from mouse to human disease. In addition, the Yale Cancer Center (YCC) funded two pilot grants in the microbiome and cancer, and established a microbiome biobank for colorectal-cancer patients that will be a valuable resource for basic and translational research. VOIC members published 333 cancer- related papers (July 1, 2012-June 1, 2017) of which 11% were intraprogrammatic and 23% interprogrammatic. VOIC cancer research funding totals $10.3M (direct) of which $9.4M is peer reviewed, a 24% increase in peer-reviewed funding relative to the last submission in 2012.!

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-39
Application #
9570294
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications